The Irvine, Calif.-based medical devicemaker expects more than half of its revenue will come from sales of its transcatheter aortic valve replacement business, which it predicts will see a 15 percent sales growth in 2020.
The company told MedTech Dive its growth estimate is based on factors including an aging population, health systems prioritizing structural heart care and increased awareness of transcatheter technologies.
The company has a history of underestimating its market goals, analysts at Jeffries, a New York City-based investment banking firm, told MedTechDive.
Read the full article here.
More articles on supply chain:
Viant to shut down sterilization operations at Michigan facility
Hahnemann hospital auctioning off medical equipment, supplies
UPS names president of healthcare unit
